Peter DeMuth
Vermogen: 8 500 $ op 31-05-2026
Vermogen: 8 500 $ op 31-05-2026
Peter DeMuth currently works at Elicio Therapeutics, Inc., as Chief Scientific Officer from 2022.
Dr. DeMuth also formerly worked at Elicio Therapeutics, Inc. (United States), as Chief Scientific Officer from 2022 to 2023.
Dr. DeMuth received his doctorate degree in 2013 from Massachusetts Institute of Technology and undergraduate degree in 2008 from the University of Maryland.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 09-04-2026 | 743 ( 0% ) | 8 500 $ | 31-05-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| ELICIO THERAPEUTICS, INC. | Hoofd Techniek/Wetenschap/O&O | 01-01-2022 |
| Bedrijven | Functie | Einde |
|---|---|---|
Elicio Therapeutics, Inc. (United States)
Elicio Therapeutics, Inc. (United States) BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops novel immunotherapies for treatment of cancer and other diseases | Hoofd Techniek/Wetenschap/O&O | 01-06-2023 |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 4 |
|---|---|
Elicio Therapeutics, Inc. (United States)
Elicio Therapeutics, Inc. (United States) BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops novel immunotherapies for treatment of cancer and other diseases | Health Technology |
Massachusetts Institute of Technology
Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
University of Maryland
University of Maryland Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Elicio Therapeutics, Inc.
Elicio Therapeutics, Inc. BiotechnologyHealth Technology Develops cancer immunotherapies | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau